Skip to main content

Navigation group

Type at least 3 characters
2,221 articles

Articles

Original Research

Published on 28 Oct 2022

OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants

in Molecular and Cellular Pathology

  • Estelle Colin
  • Yannis Duffourd
  • Emilie Tisserant
  • Raissa Relator
  • Ange-Line Bruel
  • Frédéric Tran Mau-Them
  • Anne-Sophie Denommé-Pichon
  • Hana Safraou
  • Julian Delanne
  • Nolwenn Jean-Marçais
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants
Frontiers in Cell and Developmental Biology
doi 10.3389/fcell.2022.1021785
  • 4,044 views
  • 14 citations